Glucotrack, Inc.
Business
Glucotrack, Inc. is a medical device company developing an implantable continuous blood glucose monitor (Glucotrack CBGM) for Type 1 and Type 2 diabetes patients. The device measures glucose directly from blood via an intravascular sensor with a projected lifespan of three years and minimal calibration requirements. The company is conducting preclinical and clinical studies, targeting FDA approval through an IDE submission in Q2 2026 and U.S. clinical trials in H2 2026, with parallel CE Mark certification planned for EU markets.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development expenses | 10 | 9 | 5 | 2 | 2 | |
| General and administrative expenses | 6 | 5 | 2 | 2 | 2 | |
| Total operating expenses | 16 | 15 | 7 | 4 | 4 | |
| Loss from operations | 16 | 15 | 7 | 4 | 4 | |
| Other (income) expense | −26,000 | −14,000 | — | 14,000 | 53,000 | |
| Change in fair value of derivative liability | 3 | 798,000 | — | — | — | |
| Loss on equity issuance | — | 2 | — | — | — | |
| Loss on settlement of liabilities | — | 5 | — | — | — | |
| Finance expense, net | 57,000 | 583,000 | −7,000 | — | — | |
| Total other income | 3 | 8 | — | — | — | |
| Net loss | 19 | 23 | 7 | 4 | 4 | |
| Foreign currency translation adjustment | −49,000 | −24,000 | 1,000 | −23,000 | 21,000 | |
| Comprehensive loss | 19 | 23 | 7 | 4 | 4 | |
| Basic loss per share | 31.22 | 4,106 | 34.18 | 0.29 | 0.26 | |
| Diluted loss per share | 31.22 | 4,106 | 34.18 | 0.29 | 0.26 | |
| Weighted average number of common stock outstanding used in computing basic net loss per share | 621,094 | 5,503 | 207,603 | 15 | 15 | |
| Weighted average number of common stock outstanding used in computing diluted net loss per share | 621,094 | 5,503 | 207,603 | 15 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-10-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 7 | 6 | — | 4 | 2 | |
| Other current assets | 284,000 | 151,000 | — | 376,000 | 67,000 | |
| Total current assets | 8 | 6 | — | 5 | 2 | |
| Operating lease right-of-use asset, net | 33,000 | 59,000 | — | — | — | |
| Property and equipment, net | 138,000 | 95,000 | — | 27,000 | 40,000 | |
| Restricted cash | — | 10,000 | — | 10,000 | 19,000 | |
| TOTAL ASSETS | 8 | 6 | — | 5 | 2 | |
| Accounts payable | 1 | 992,000 | — | 839,000 | 672,000 | |
| Operating lease liability, current | 28,000 | 26,000 | — | — | — | |
| Promissory notes | 3 | — | — | — | — | |
| Convertible promissory notes | — | 5,000 | — | — | — | |
| Other current liabilities | 246,000 | 252,000 | — | 673,000 | 341,000 | |
| Total current liabilities | 5 | 1 | — | 2 | 1 | |
| Derivative financial liabilities | 1,000 | 17 | 17 | — | — | |
| Operating lease liability, non-current | 5,000 | 33,000 | — | — | — | |
| Loans from stockholders | 231,000 | 203,000 | — | 196,000 | 195,000 | |
| Total liabilities | 5 | 19 | — | 2 | 1 | |
| Commitments and contingent liabilities (Note 5) | — | — | — | — | — | |
| Common Stock of $0.001 par value (Common Stock): 100,000,000 shares authorized as of December 31, 2025 and 2024; 910,688 and 13,409 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1,000 | 1,000 | — | — | 15,000 | |
| Additional paid-in capital | 151 | 119 | — | 113 | 103 | |
| Receipts on account of shares | 4 | 228,000 | — | 48,000 | 4,000 | |
| Accumulated other comprehensive income | 41,000 | −8,000 | — | 16,000 | 17,000 | |
| Accumulated deficit | −152 | −132 | — | −110 | −102 | |
| Total stockholders (deficit) equity | 3 | −13 | — | 3 | 1 | |
| TOTAL LIABILITIES AND STOCKHOLDERS (DEFICIT) EQUITY | 8 | 6 | — | 5 | 2 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 42,000 | 36,000 | 13,000 | 23,000 | 42,000 | |
| Loss on fixed asset disposal | 16,000 | — | — | — | — | |
| Equity issuance costs | — | 1 | — | — | — | |
| Stock-based compensation | 211,000 | 173,000 | 281,000 | 439,000 | 223,000 | |
| Issuance of restricted shares as compensation to directors | 122,000 | 306,000 | 54,000 | 48,000 | 38,000 | |
| Amortization of original issue discount related to promissory note | 182,000 | — | — | — | — | |
| Shares issued to CEO for achieving of IP Agreement milestones | — | 192,000 | — | — | — | |
| Loss on Series A warrant repurchase | 99,000 | — | — | — | — | |
| Discount amortization and interest expenses related to promissory notes | — | 628,000 | — | — | — | |
| Linkage difference on principal of loans from stockholders | — | 7,000 | 1,000 | 11,000 | 6,000 | |
| Decrease (increase) in other current assets | −133,000 | 225,000 | −309,000 | −28,000 | 15,000 | |
| Increase in accounts payable | 325,000 | 263,000 | 167,000 | — | — | |
| Increase (decrease) in other current liabilities | 17,000 | −421,000 | 332,000 | 138,000 | −172,000 | |
| Net cash used in operating activities | −15 | −12 | −7 | −4 | −4 | |
| Purchase of property and equipment | −96,000 | −104,000 | — | −1,000 | −5,000 | |
| Net cash used in investment activities | −96,000 | −104,000 | — | 1,000 | −1,000 | |
| Net proceeds received from underwritten U.S. public offering | 11 | 9 | — | — | — | |
| Proceeds from promissory note, net of original issue discount of $600 | 3 | — | — | — | — | |
| Series A warrant repurchase | −166,000 | — | — | — | — | |
| Net proceeds from December 2025 private placement transaction | 4 | — | — | — | — | |
| Issuance of promissory notes and detachable warrants through private placement Transaction | — | 100,000 | — | — | — | |
| Issuance of convertible promissory notes - related parties | — | 4 | — | — | — | |
| Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction | — | 360,000 | — | — | — | |
| Net proceeds received from underwritten U.S. public offering | — | 500,000 | 9 | — | — | |
| Net cash provided by financing activities | 17 | 14 | 9 | — | — | |
| Effect of exchange rate changes on cash and cash equivalents | 49,000 | −24,000 | −1,000 | −54,000 | −2,000 | |
| Change in cash, cash equivalents, and restricted cash | 2 | 1 | 2 | −4 | −4 | |
| Interest | −52,000 | −62,000 | — | — | — | |
| Fair value of equity classified warrants issued in connection with December 2025 private placement | 8 | — | — | — | — | |
| Recognition of right for use asset against a lease liability | — | 79,000 | — | — | — | |
| Settlement of liabilities with equity | — | 2 | — | — | — | |
| Derivative liability | — | 35,000 | — | — | — | |
| Conversion of debt into equity | — | 2 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Glucotrack, Inc.'s CIK number?
Glucotrack, Inc.'s SEC CIK number is 0001506983 (1506983). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Glucotrack, Inc.'s SEC filings?
All of Glucotrack, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Glucotrack, Inc. last report earnings?
Glucotrack, Inc. (GCTK) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-023202). This is Glucotrack, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Glucotrack, Inc.'s most recent earnings 8-K?
Glucotrack, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001493152-26-023202. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Glucotrack, Inc.'s latest earnings 8-K →
Look up any company's CIK number →